- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
PMV Pharmaceuticals Short Interest Drops 18.8%
Approximately 3.1% of the company's shares are currently sold short.
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) saw a significant decrease in short interest in February, with the number of shares sold short dropping 18.8% from the end of January. As of February 13th, around 3.1% of the company's shares were sold short, with the short-interest ratio currently at 5.7 days based on the average daily trading volume.
Why it matters
Short interest can provide insights into investor sentiment and potential future stock price movements. The drop in short interest for PMV Pharmaceuticals may signal that some investors are becoming more bullish on the stock.
The details
According to the report, as of February 13th, there was short interest totaling 1,503,564 shares of PMV Pharmaceuticals, a decrease of 18.8% from the January 29th total of 1,851,701 shares. Approximately 3.1% of the company's shares are currently sold short, with the short-interest ratio standing at 5.7 days based on the average daily trading volume of 265,492 shares.
- As of February 13th, 2026
- As of January 29th, 2026
The players
PMV Pharmaceuticals, Inc.
A precision oncology company that engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
Acadian Asset Management LLC
A hedge fund that increased its position in PMV Pharmaceuticals by 0.9% during the second quarter of 2026.
BML Capital Management LLC
A hedge fund that grew its stake in PMV Pharmaceuticals by 33.4% during the second quarter of 2026.
Stonepine Capital Management LLC
A hedge fund that increased its position in PMV Pharmaceuticals by 34.2% during the second quarter of 2026.
PNC Financial Services Group Inc.
A financial services company that lifted its stake in PMV Pharmaceuticals by 16.7% in the third quarter of 2026.
The takeaway
The drop in short interest for PMV Pharmaceuticals could signal that some investors are becoming more optimistic about the company's prospects, though the stock still has a 'Hold' rating from analysts. Investors will want to monitor the company's progress and any further changes in short interest going forward.
